Risk of cancer and serious disease in Danish patients with urgent referral for serious non-specific symptoms and signs of cancer in Funen 2014-2021

被引:2
|
作者
Gronnemose, Rasmus Birkholm [1 ]
Hansen, Per Syrak [1 ]
Worsoe Laursen, Soren [2 ]
Gerke, Oke [3 ,4 ]
Kjellberg, Jakob [5 ]
Lykkegaard, Jesper [6 ]
Thye-Ronn, Clara [1 ]
Hoilund-Carlsen, Poul Flemming [4 ]
Thye-Ronn, Peter [1 ]
机构
[1] Odense Univ Hosp, Svendborg Hosp, Diagnost Ctr, Svendborg, Denmark
[2] Danish Canc Soc, Copenhagen, Denmark
[3] Odense Univ Hosp, Dept Nucl Med, Odense, Denmark
[4] Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, Odense, Denmark
[5] Danish Ctr Social Sci Res, VIVE, Copenhagen, Denmark
[6] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
DIAGNOSTIC INTERVALS; GENERAL-PRACTICE; SURVIVAL; SWEDEN; UK; PATHWAY; GUIDELINES; AUSTRALIA; DENMARK; NORWAY;
D O I
10.1038/s41416-024-02620-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIn 2011, as the first European country, Denmark introduced the non-organ-specific cancer patient pathway (CPP) for patients presenting with non-specific symptoms and signs of cancer (NSSC). The proportion of patients with cancer over time is unknown.MethodsA retrospective cohort study of all patients with a NSSC-CPP investigational course in the province of Funen to the Diagnostic Centre in Svendborg from 2014 to 2021 was performed to evaluate the proportion of patients with cancer and serious disease over time.ResultsA total of 6698 patients were referred to the NSSC-CPP of which 20.2% had cancer. While the crude referral rate increased from 114 per 100,000 people in 2014 and stabilised to around 214 in 2017-2021, the cancer detection rate of the total yearly new cancers in Funen diagnosed through the NSSC-CPP in DC Svendborg increased from 3 to 6%.ConclusionsWith now high and stable conversion and crude referral rates, the NSSC-CPP is one of the largest CPPs in Denmark as measured by the number of new cancer cases found. Similar urgent referral programmes in other countries might fill an unmet medical need for patients presenting with serious non-specific symptoms and signs of cancer in general practice.
引用
收藏
页码:1304 / 1315
页数:12
相关论文
共 50 条
  • [41] Algorithm Assignment to Stereotactic Body Radiation Therapy Is Associated with High Risk of Post-Surgical Serious Adverse Events in Stage I Non-small Cell Lung Cancer Patients
    Samson, P.
    Roach, M. C., Jr.
    Carpenter, L.
    Bradley, J. D.
    Kozower, B.
    Puri, V.
    Meyers, B.
    Robinson, C. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E530 - E531
  • [42] Disparities in referral by risk profile for genetic counseling of high-risk individuals: A disease-specific analysis of mutation frequencies of 1,193 patients presenting for presumptive hereditary breast ovarian cancer (HBOC) or colorectal cancer syndromes (CCS).
    Shapira, I.
    Gralla, R. J.
    Sultan, K. S.
    John, V. S.
    Devoe, C. E.
    D'Olimpio, J. T.
    Raftopoulos, H.
    Donahue, L.
    Vinciguerra, V.
    Cohen, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Specific patterns and potential risk factors to predict 3-year risk of death among non-cancer patients with advanced chronic kidney disease by machine learning
    Chang, Tzu-Hao
    Chen, Yu-Da
    Lu, Henry Horng-Shing
    Wu, Jenny L.
    Mak, Katelyn
    Yu, Cheng-Sheng
    MEDICINE, 2024, 103 (07) : E37112
  • [44] Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests(SEDRT) (CARG plus CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients.
    Carreca, Ignazio Ugo
    Bazan, Viviana
    Galvano, Antonio
    Carreca, Anna Paola
    Cusenza, Stefania
    Russo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] DEPRESSIVE SYMPTOMS AND RISK OF CANCER-SPECIFIC MORTALITY AMONG OLDER PATIENTS WITH NON-HODGKIN LYMPHOMA: ANALYSES FROM THE SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER) MEDICARE HEALTH OUTCOMES SURVEY (MHOS)
    Asfaw, A. A.
    Talon, B.
    Nabulsi, N.
    Alobaidi, A.
    Zhou, J.
    Sweiss, K.
    Patel, P.
    Chiu, B.
    Calip, G. S.
    VALUE IN HEALTH, 2019, 22 : S89 - S89
  • [46] MEASURING DISEASE AND TREATMENT-RELATED SYMPTOMS AND HRQOL IMPACTS IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) USING THE EORTC QLQ-C30 AND NMIBC-24: QUALITATIVE LITERATURE REVIEW AND GAP ANALYSIS
    Mason, B.
    Eccleston, A.
    Ayala, Nunes L.
    Chandrasekar, S.
    Leventi, A.
    Gater, A.
    Chang, J.
    VALUE IN HEALTH, 2024, 27 (06) : S327 - S328
  • [47] EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin
    Cambier, Samantha
    Sylvester, Richard J.
    Collette, Laurence
    Gontero, Paolo
    Brausi, Maurizio A.
    van Andel, George
    Kirkels, Wim J.
    Da Silva, Fernando Calais
    Oosterlinck, Willem
    Prescott, Stephen
    Kirkali, Ziya
    Powell, Philip H.
    de Reijke, Theo M.
    Turkeri, Levent
    Collette, Sandra
    Oddens, Jorg
    EUROPEAN UROLOGY, 2016, 69 (01) : 60 - 69
  • [49] Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
    Williams, Stephen B.
    Kamat, Ashish M.
    EUROPEAN UROLOGY, 2016, 69 (06) : E121 - E122
  • [50] Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
    Sylvester, Richard
    Gontero, Paolo
    Oddens, Jorg
    EUROPEAN UROLOGY, 2016, 69 (06) : E123 - E124